Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Viewpoint - Cardiol Therapeutics Inc. is set to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, focusing on its clinical-stage anti-inflammatory and anti-fibrotic therapies for heart disease [1]. Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in the research and development of therapies targeting inflammation and fibrosis in heart disease [3]. - The company's lead drug candidate, CardiolRx™ (cannabidiol) oral solution, is in clinical development and aims to inhibit the inflammasome pathway, which is crucial in the progression of inflammation and fibrosis related to heart conditions [3]. Clinical Development - Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4]. - The MAVERIC Program addresses recurrent pericarditis, which can lead to severe symptoms and reduced quality of life, and includes a completed Phase II study and an ongoing Phase III trial [4]. - The ongoing ARCHER trial is a Phase II study focusing on acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults [4]. Additional Developments - Cardiol is also developing CRD-38, a novel subcutaneous formulation intended for heart failure treatment, which is a leading cause of death and hospitalization, with healthcare costs in the US exceeding $30 billion annually [5].